[Inhibition of rat corneal neovascularization by inhibitor of nuclear factor-kappaB].
OBJECTIVE
To observe the effects and mechanism of pyrrolidine dithiocarbamate (PDTC) on inhibiting corneal neovascularization.


METHODS
The corneal neovascularization was induced by alkali burn in 48 Sprague-Dawley rats. The rats were randomly divided into 4 groups, 12 rats in each group. The PDTC eye drops with different concentrations were applied four times daily during days 0 - 28 in each group: 0.5 mg/ml in group A, 1 mg/ml in group B, 2 mg/ml in group C and 0.9% sodium chloride in group D (control). The development of corneal neovascularization and corneal opacity were observed daily with slit lamp. Corneas were excised at day 4 and 28 (six eyes were selected randomly in each group per time) for histopathological examinations. The expression of nuclear factor-kappaB (NF-kappaB) in the cornea was examined by Western Blot.


RESULTS
The corneal neovascularization area in groups B and C were significantly smaller than that in the control group (P < 0.01). The corneal opacification and inflammation level in groups B and C were also lower than that in the control group. No significant difference was found in corneal neovascularization areas and corneal opacification levels between group A and group D (P > 0.05). The activity of NF-kappaB in groups B and C was significantly lower than that of group D. No significant difference in NF-kappaB could be detected between group A and group D.


CONCLUSIONS
Topical application of PDTC has significant effects on the inhibition of activation of NF-kappaB and cornea neovascularization.
Wang
Yong
Y
Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. yong_wang@hotmail.com
Zhang
Ming-chang
MC
Hu
Yi-zhen
YZ
Yu
Chang-tai
CT
D000818:Animals; D003315:Cornea / Q000378:metabolism / Q000473:pathology; D016510:Corneal Neovascularization / Q000378:metabolism / Q000517:prevention & control*; D005126:Eye Burns / Q000378:metabolism / Q000473:pathology; D005260:Female; D008297:Male; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000517:prevention & control*; D011392:Proline / Q000031:analogs & derivatives* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013859:Thiocarbamates / Q000494:pharmacology*
D016328:NF-kappa B; D013859:Thiocarbamates; C066229:prolinedithiocarbamate; D011392:Proline